HeberNasvac: Development and Application in the Context of Chronic Hepatitis B
2024; Volume: 14; Issue: 2 Linguagem: Inglês
10.5005/jp-journals-10018-1457
ISSN2231-5128
AutoresMamun Al-Mahtab, Osamu Yoshida, Yoichi Hiasa, Sheikh MF Akbar, Guillermo Fernández–Varo, Jorge Aguiar, Eduardo Pentón, Md. Sakirul Islam Khan, Gerardo Guillén, Julio Aguilar, Carlos A. Guzmán, Marie-Louise Michel, Maryline Bourgine, Maria A. Marrero, Stephanie Trittel, Thomas Ebensen, Peggy Riese, Roger Le Grand, Cécile Hérate, Aurélie Mauras,
Tópico(s)Hepatitis Viruses Studies and Epidemiology
ResumoThe immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation. Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
Referência(s)